ERS statement: a core outcome set for clinical trials evaluating the management of COPD exacerbations.
Mathioudakis AG, Abroug F, Agusti A, Ananth S, Bakke P, Bartziokas K, Beghe B, Bikov A, Bradbury T, Brusselle G, Cadus C, Coleman C, Contoli M, Corlateanu A, Corlateanu O, Criner GJ, Csoma B, Emelyanov A, Faner R, Fernandez Romero G, Hammouda Z, Horváth P, Huerta Garcia A, Jacobs M, Jenkins C, Joos G, Kharevich O, Kostikas K, Lapteva E, Lazar Z, Leuppi JD, Liddle C, Linnell J, López-Giraldo A, McDonald VM, Nielsen R, Papi A, Saraiva I, Sergeeva G, Sioutkou A, Sivapalan P, Stovold E, Wang H, Wen F, Yorke J, Williamson PR, Vestbo J, Jensen JU; DECODE-NET.
Mathioudakis AG, et al. Among authors: coleman c.
Eur Respir J. 2022 May 5;59(5):2102006. doi: 10.1183/13993003.02006-2021. Print 2022 May.
Eur Respir J. 2022.
PMID: 34649975
Free article.